Structure determination of APO I95P mutant from Mycobacterium tuberculosis

The Enoyl-acyl-carrier protein reductase from Mycobacterium tuberculosis (InhA) is an
essential enzyme for this pathogen's survival and the main target for Isoniazid, which is one
of the first-line drugs used for tuberculosis treatment. Missense mutations affecting this
protein have been correlated with resistance to Isoniazid, but the resistance mechanisms
involved have not been completely elucidated to date. We aim to obtain structural data by
Cryo-EM for the APO state of the mutant I95P, which usually
crystallography does not work. Obtaining these results might contribute to understanding the
molecular basis of resistance to Isoniazid.